

Salicylic Acid sans Aspirin in Animals and Man: Persistence in Fasting and Biosynthesis from Benzoic Acid

JOHN R. PATERSON,^{†,§} GWENDOLINE BAXTER,^{*,§} JACOB S. DREYER,[§]
JOHN M. HALKET,[#] ROBERT FLYNN,[§] AND JAMES R. LAWRENCE[§]

Dumfries and Galloway Royal Infirmary, Bankend Road, Dumfries DG1 4AP, United Kingdom, and
Centre for Chemical Sciences, Royal Holloway, Egham TW20 0EX, United Kingdom

Salicylic acid (SA), which is central to defense mechanisms in plants and the principal metabolite of aspirin, occurs naturally in man with higher levels of SA and its urinary metabolite salicyluric acid (SU) in vegetarians overlapping with levels in patients on low-dose aspirin regimens. SA is widely distributed in animal blood. Fasting for major colorectal surgery did not cause disappearance of SA from plasma, even in patients following total proctocolectomy. A ¹³C₆ benzoic acid load ingested by six volunteers led, between 8 and 16 h, to a median 33.9% labeling of urinary salicyluric acid. The overall contribution of benzoic acid (and its salts) to the turnover of circulating SA thus requires further assessment. However, that SA appears to be, at least partially, an endogenous compound should lead to reassessment of its role in human (and animal) pathophysiology.

KEYWORDS: Salicylic acid; aspirin; benzoic acid; synthesis; salicyluric acid

INTRODUCTION

In plants, salicylic acid (SA) is a ubiquitous secondary metabolite pivotally concerned in initiation of the response to a variety of physical, chemical, and biological insults (1). The potent analgesic and antipyretic properties of plant extracts, notably dried myrtle leaves and willow bark, had been known for many centuries before the isolation of salicylic acid, as the likely active principle, by Meyer in 1870 (2). Since synthesis of aspirin (acetylsalicylic acid) by Hoffman in 1897, investigation has focused on the properties of that compound—designed as a pro-drug. Aspirin is very rapidly hydrolyzed, having a plasma *t*_{1/2} of 20 min, to the deacetylated metabolite SA (2-hydroxybenzoic acid), which has a half-life of between 2 and 4 h (3). However, the demonstration that aspirin acts by serine side-chain acetylation of Cox-1 and Cox-2 isoforms, restricting substrate access to the active sites of these enzymes, has deflected attention from salicylic acid itself, although in vivo SA is, despite weak, reversible Cox-1 and absent Cox-2 inhibition, as effective as aspirin in suppressing inflammation (4). The inhibition of transcription of the Cox-2 gene by micromolar concentrations of SA (5, 6) is the likely explanation.

Previous work by our group has demonstrated and confirmed the presence of SA in serum (7) and urine (8), where its metabolite salicyluric acid (SU) predominates, from individuals who had not recently consumed aspirin. The measured levels

were significantly higher in vegetarians (9, 10), overlapping with levels in patients on low-dose aspirin regimens, and our past publications have focused on a dietary origin (11) of this naturally occurring SA in man. However, confirmation of the contribution from fruit and vegetable consumption in the diet to circulating SA levels in man (12) has demonstrated that <20% of the variability in serum SA, measured by a sensitive specific method, may derive from that source. Some circulating SA in aspirin-naïve or -free individuals could possibly derive from another dietary source or be of nondietetic origin.

In plants, SA is synthesized through the shikimic acid pathway via isochorismate (13) or, probably predominantly, by the phenyl-propanoid route via cinnamic and benzoic acids (14). Benzoic acid is a natural constituent of plants, with high amounts being found in fruits and berries (15, 16). That hippuric acid, the main metabolite of benzoic acid, may be formed endogenously in man was demonstrated by formula diet feeding (17, 18). In the Sprague–Dawley rat a radiolabel experiment showed phenylalanine to be the likely precursor (17). Use of the generally regarded as safe (GRAS) sodium benzoate as a food preservative also contributes to human intake. With regard to levels of regular intake, the FDA estimate is of 0.9–34 mg/day as benzoic acid and 34–328 mg/day as sodium benzoate, although much higher levels of sodium benzoate—up to 5 g twice daily—have been used therapeutically in the treatment of acute hepatic encephalopathy. Thus, in this paper we have determined whether the addition of benzoic acid to a standardized diet produced any change in serum or urinary salicylates.

* Corresponding author (e-mail Gwen.baxter@nhs.net).

[†] Deceased.

[§] Dumfries and Galloway Royal Infirmary.

[#] Centre for Chemical Sciences.




Figure 1. Salicylic acid in pooled urine sample: (a) partial mass spectrum obtained by gas chromatography–mass spectrometry of a trimethylsilylated extract of pooled urine (isotopically labeled peaks are indicated by asterisks at m/z values 199, 212, and 330); (b) partial library mass spectrum of the di-trimethylsilyl derivative of standard salicylic acid (*o*-hydroxyhippuric acid). Data were analyzed using the Automated Mass Spectral Deconvolution and Identification System (AMDIS; NIST, Gaithersburg, MD; <http://chemdata.nist.gov/mass-sps/amdis>).

MATERIALS AND METHODS

Blood samples, serum or plasma, were obtained from animals at the London Zoo or at the Department of Biological Services, University of Glasgow. Blood was collected according to the approved codes of practice of these institutions.

Six mice were treated with neomycin, 100 mg/kg/day, for 4 days prior to collection of blood to reduce as much as possible the bacterial content of their gastrointestinal tracts. Samples from germ-free Sprague–Dawley rats were obtained from Charles River Ltd., Margate, Kent, U.K.

All human studies were approved by the Dumfries and Galloway Health Board Ethics Committee. Serum salicylic acid (SA) and urinary SA and salicylic acid (SU) levels were assayed according to the HPLC methods described previously (7, 8).

The absence of any SA from the milk diet used in the preliminary controlled diet study was confirmed by total SA assay as we have previously described (11).

A pilot study, to assess whether ingestion of benzoic acid might raise endogenous SA levels, utilized weighed preprepared meals (requiring only reheating) replicating exactly the same menu and fluid intake over each 4 days. Throughout, urine samples were collected every 12 h. Fasting blood samples were obtained daily and on the morning of day 5. Two individuals were studied over 4 days of diet standardization after being aspirin-free for 2 weeks; the benzoic acid doses used were 1 g/day on days 3 and 4 in one subject and 2 g/day on these days in the other.

Subsequently, a labeled study was undertaken over 3 days in six individuals (four males, two females, ages 30–62 years) using a standard protocol. On day 2 all six individuals received 1 g of uniformly ring-labeled ^{13}C benzoic acid with each of their three main meals. Very minor gastric upset was the only side effect in an individual who preferred to take the benzoic acid unencapsulated.

For that experiment uniformly ring-labeled ^{13}C benzoic acid (ring- ^{13}C 99% pure) was supplied by Cambridge Isotope Laboratories Inc. USA. Food and fluid intake over the 3 days of the study were standardized. Each individual completed a detailed diary of all oral intake on day 1 and replicated that diet as closely as possible over the next two days. Cumulative urine samples were collected every 8 h over the whole 72 h of the study. The blood sampling protocol followed as closely as possible was day 1, 5×2 h, and days 2 and 3, 8×2 h, the first sample on each day being taken fasting. The serum SA levels were analyzed as areas under the SA level time curves over 0–6 h only as missing values precluded 0–8 h analysis. Statistical analysis of the total urinary SA and SU results was by nonparametric Friedman two-way analysis of variance, using SPSS version 12.

Gas chromatography–mass spectrometry (GC-MS) of the day 2, 8–16 h, urine samples was then performed. Preliminary fractionation was as described previously (8); samples prepared without internal standard were chromatographed under the usual conditions (with the

electrochemical detector inactive), and the fraction between 1 min prior to the retention time (t_R) of SU and 1 min after the t_R of SA was collected.

Trimethylsilyl derivatives were prepared by treating the dried extracts with a mixture of acetonitrile and *N,O*-bis(trimethylsilyl)trifluoroacetamide (50:50, v/v, 30 min, 60 °C).

GC-MS analysis was carried out on an Agilent 6890/5973 MSD system (30 m \times 0.25 mm i.d. DB5MS column) using both scanning and selected ion monitoring methods. The main ion fragments of interest were for SA m/z 267 (unlabeled) and m/z 273 (labeled) and for SU m/z 324 (unlabeled) and m/z 330 (labeled).

To obtain the mass spectra shown in part in **Figure 1**, aliquots of all of the second-day 8–16 h urine samples were initially pooled prior to derivatization. Data files were analyzed by the Automated Mass Spectral Deconvolution and Identification System (AMDIS; NIST, Gaithersburg, MD; <http://chemdata.nist.gov/mass-spc/amdis/>).

Further aliquots from individual samples were then fractionated, derivatized, and analyzed by selected ion monitoring to give the individual results. The ratios quoted were calculated from the m/z ratios of 273/267 for $^{13}\text{C}_6$ SA and 330/324 for $^{13}\text{C}_6$ SU.

RESULTS

As **Table 1** shows, those species regarded as primarily carnivorous had blood SA levels comparable to those measured in herbivores. The highest levels we detected were in the range associated with aspirin use in man, as comparison with our appended published results (9, 11) shows, and only the crustacean samples examined did not contain SA.

To examine the possibility of a gastrointestinal bacterial source for SA, two small groups of germ-free mice were assayed for SA. The pooled serum from six mice treated with neomycin, 100 mg/kg/day, for 4 days before sacrifice had a slightly higher concentration of SA in serum (0.309 $\mu\text{mol/L}$) than the pooled serum sample from six untreated animals (0.268 $\mu\text{mol/L}$). Another germ-free animal model studied was the Sprague–Dawley rat delivered by caesarean section, reared in a sterile environment, and fed sterilized food. A group of eight such germ-free animals had a pooled serum SA level of 0.166 $\mu\text{mol/L}$, approximately 2.5 times greater than the pooled serum salicylic acid level of 0.069 $\mu\text{mol/L}$ from a group of control animals. The net effect of minimizing or eliminating a contribution from colonic bacteria in these animal models was therefore enhancement of serum SA levels in the host animal.

Throughout the preliminary controlled diet study, in a subject who had taken no aspirin during the previous 2 weeks, there was persistence of measurable serum SA throughout 3 days on a milk/water diet (which was confirmed by analysis to be free

Table 1. Concentration of Salicylic Acid (SA) in the Blood of a Variety of Animals

Results in Animals								
animal	phylogenetic class	[SA] ($\mu\text{mol/L}$)	animal	phylogenetic class	[SA] ($\mu\text{mol/L}$)	animal	phylogenetic class	[SA] ($\mu\text{mol/L}$)
burrowing owl	Aves	9.854	tiger	Mammalian	0.661 ^a	Chinese alligator	Reptilia	0.156
ne-ne	Aves	5.609	brown trout	Pisces	0.538	domestic cat	Mammalian	0.144
Indian rhinoceros	Mammalian	4.700	giraffe	Mammalian	0.507	pond heron	Aves	0.136
pygmy hippopotamus	Mammalian	2.384	donkey	Mammalian	0.473	gorilla	Mammalian	0.125
agouti	Mammalian	2.116	sacred ibis	Aves	0.353	red faced spider monkey	Mammalian	0.080
Asian elephant	Mammalian	1.635	goat	Mammalian	0.310	mouse	Mammalian	0.078
Burmese python	Reptilia	1.362	giant anteater	Mammalian	0.293	rat	Mammalian	0.069
rabbit	Mammalian	1.129	collared peccary	Reptilia	0.237	domestic cat (fed only meat)	Mammalian	0.058
piglet	Mammalian	1.010	African lion	Mammalian	0.226 ^a	chimpanzee	Mammalian	0.033
Arabian oryx	Mammalian	0.777	cow	Mammalian	0.216	European shore crab	Crustacea	<0.005
sheep	Mammalian	0.715	Gelada baboon	Mammalian	0.210	prawn	Crustacea	<0.005

Results in Man (9, 11)		
	median ($\mu\text{mol/L}$)	range ($\mu\text{mol/L}$)
vegetarians, $n = 37$	0.110	0.04–2.47
nonvegetarians, $n = 39$	0.070	0.02–2.00
southern Indian villagers, $n = 21$	0.763	0.05–0.64
75 mg aspirin takers, $n = 14$	10.03	0.23–25.40
limit of detection of the method = 0.005 $\mu\text{mol/L}$		

^a Mean concentration in five animals.**Table 2.** Patient Profile

no. of obs	patient	gender	age (years) at time of diagnosis	diagnosis	procedure/operation	days prior to eating ^a	serum SA ($\mu\text{mol/L}$) median (range)	lowest urine (SA + SU, $\mu\text{mol/24 h}$, median)
15	1	male	39	ulcerative colitis	total colectomy with ileostomy	2	0.0624 (0.054–0.082)	0.368
6	2	female	59	with toxic megacolon second colon cancer	panproctocolectomy	3	0.037 (0.013–0.074)	0.470
12	3	female	68	with multiple polyps carcinoma of rectum	abdomino-perineal resection	5	0.045 (0.012–0.132)	7.707
11	4	male	47	carcinoma of colon	extended r. hemicolectomy	2	0.074 (0.061–0.088)	0.288
4	5	female	64	carcinoma of rectum	low ant. resection of rectum	2	0.34 (0.079–0.847)	1.01
3	6	male	66	carcinoma of rectum + second cancer in cecum	panproctocolectomy with ileostomy	2	0.103 (0.063–0.174)	1.84

^a Patients were either fasting or receiving parenteral nutrition with no salicylic acid content (confirmed by assay).

from SA). In that experiment urine excretion of SA + SU continued at a rate of around 2.1 $\mu\text{mol/24 h}$ throughout the period of dietary restriction. Blood samples were assayed for SA at 12 h intervals, and the serum SA levels did not change significantly, not falling below 0.1 $\mu\text{mol/L}$ (20 times the limit of detection of the assay) over the 72 h of the study. These data suggested that another source of SA was responsible for the persistence of serum SA and the steady rate of excretion of SA + SU throughout the time course of this experiment.

In six patients (**Table 2**) who had total colectomy or rectal excision following standard preoperative bowel preparation low-level serum SA (range = 0.012–0.0847 $\mu\text{mol/L}$) was detected and urinary SA + SU excretion persisted (median of individual lowest levels = 0.613 $\mu\text{mol/24 h}$, range = 0.184–7.607) in all subjects, for up to 5 days postoperatively, rising only on refeeding.

During the pilot benzoic acid study in two subjects there was little variation in serum SA levels, which were in the ranges of 0.44–0.53 and 0.023–0.047, respectively, with no downward trend over the course of the experiment. The rate of combined SA and SU excretion in urine, however, increased from median levels of 3.87 (range = 3.47–4.32) and 4.50 (range = 4.39–4.62) $\mu\text{mol/24 h}$ over the first 3 days of the study to 5.10 and 7.04 $\mu\text{mol/24 h}$, respectively, on day 4. That increase was

greater in the subject who had consumed 2 g of benzoic acid per day on days 3 and 4.

Further examination of the possible biosynthesis of SA in man required a labeled precursor study. That showed variability in total serum SA during the study, but in every individual the highest serum SA measured during the 3 days occurred during day 2—at a median time of 4 h (range = 2–8 h) after the first dose of benzoic acid. The areas under the SA level time curves confirmed the highest serum levels were reached on day 2, but that was not significant. The highest level (**Figure 2**, $p = 0.052$) of combined SA + SU urinary excretion was observed in the 8–16 h sample after the initial dose of benzoic acid.

To ascertain whether any of the $^{13}\text{C}_6$ label in the benzoic acid administered could be detected in salicylates, we therefore focused on the day 2, 8–16 h urine.

No $^{13}\text{C}_6$ was detected in the samples obtained prior to ingestion of labeled benzoic acid. In **Figure 1** the marked peaks (*) indicate fragments from the presence of the (six ringed) ^{13}C -labeled SU derivative (m/z 330), 6 mass units higher than the unlabeled SU derivative (m/z 324). The ^{13}C isotope was also confirmed in all six individual urine, day 2, 8–16 h samples and accounted, by selective ion monitoring, for 0.4–10.9% (median = 3.4%) in the SA derivative and 6.8–43.1% (median = 33.9%) in the SU derivative (**Table 3**). In addition, consider-




Figure 2. Urinary SA + SU excreted throughout time course of $^{13}\text{C}_6$ experiment: total SA + SU excreted during the 8 h urine collection periods. The columns represent the median value and the error bars the maximum and minimum values. The dotted line at 24 h shows the point at which the first dose of benzoic acid was introduced. One subject was omitted because of incomplete data.

Table 3. Isotopic Enrichment of Salicylic Acid (SA) and Salicylic Acid (SU) in Individual Urines^a

sample	SA % $^{13}\text{C}_6$ <i>m/z</i> 273/267	SU % $^{13}\text{C}_6$ <i>m/z</i> 330/324
urine 1	0.06	31.29
urine 2	3.31	43.07
urine 3	0.41	6.82
urine 4	10.91	36.53
urine 5	3.50	23.96
urine 6	5.45	36.98
pooled urine (no $^{13}\text{C}_6$)	0.00	0.00
standard soln SA	0.00	0.00
standard soln SU	0.00	0.00

^a Urines 1–6 show the relevant *m/z* ratio values, for each individual, of $^{13}\text{C}_6$ -labeled urinary salicylic acid (SA) and salicylic acid (SU) SA, unlabeled 267, labeled 273 SU, unlabeled 324, labeled 330. Also shown are results for pooled, unlabeled (day 1) urine and for standard solutions of SA and SU.

able amounts of the expected $^{13}\text{C}_6$ -labeled hippuric acid were found (data not shown).

DISCUSSION

There is now no doubt that salicylic acid and its salts are components of the human diet (11, 19–22). Although the bioavailability of dietary salicylates was estimated to be low (23), it is clear that serum SA levels in some aspirin-free vegetarian subjects and populations (9, 11) overlap with those of patients on low-dose aspirin regimens. One particularly revealing recent observation, in a study which confirmed that circulating SA levels related to fruit and vegetable consumption, was that <20% of the variability in serum SA derived from that source (12).

Results of SA levels in a large variety of animals showed that those species regarded as primarily carnivorous had levels comparable to those measured in herbivores. Some bacteria, notably mycobacterial, yersinia, and pseudomonas species, synthesize SA to enhance iron chelation, so there was a possibility that gut, particularly colonic, bacteria might be the source of SA not readily explicable by lack of dietary exposure. However, preliminary study of two germ-free animal models reported here showed the net effect of minimizing or eliminating a contribution from colonic bacteria was, in fact, an increase in serum SA levels.

It was these animal observations which led us to postulate that serum SA levels in aspirin-free individuals may be, at least partially, endogenous. That salicylate levels in serum and urine

plateaued in a subject on a water/milk diet for 3 days should be considered in light of a SA half-life of 4 h, which would cause the serum SA level to fall to $\sim 0.004\%$ of its initial level at the end of this time interval. The levels of serum SA in the fasting surgical patients study supported these milk diet observations. Persistence of low levels of serum SA and combined urinary SA + SU excretion in the two patients who had panproctocolectomy, and therefore no colonic or dietary source of SA, was considered to be particularly strong evidence for an endogenous source of this simple organic molecule.

The recourse to benzoic acid as a possible SA precursor in man was directed by the relevant plant biochemistry (14) and its prevalence in fruits and berries (15, 16). Benzoic acid may also be considered to be formed *in vivo* (17, 18) and is well-known to be an acceptable diet additive.

Given the relatively high doses (1–2 g/day) used in the preliminary benzoic acid study, the increase in SA levels observed on the last day of that protocol might be thought to be a little disappointing. The findings led us to use a slightly higher benzoic acid dose for the labeled study. Even with that higher benzoic acid dose, the increased total SA and SU urinary excretion was not significant, although clearly very marked in some individuals. Whereas the renal excretion of SA depends strongly on pH and the presence of organic acids as well as urinary flow rate (3), these possible confounding factors should reduce SA plus SU excretion under the conditions of this small study. Moreover, in a study of SA metabolism (to SU) using the isolated perfused rat kidney, the addition of the competitive substrate benzoic acid produced a rapid formation and excretion of hippuric acid with corresponding inhibition of SU formation and excretion (24). It would not, therefore, be surprising if use of a larger dose of benzoic acid in a greater number of subjects should lead to significantly increased total salicylate excretion. However, it is likely that naturally occurring benzoic acid was contributing to the modest 20% variability in serum SA from fruits and vegetables in the diet (12), although the added sodium benzoate content of diets with considerable fruit and vegetable content would probably be low. Given the widespread use of sodium benzoate as an additive food preservative, further work on its contribution to serum SA levels may be justified. However, set against the nonsignificant increase of total SA and SU levels in the day 2 8–16 h urines, the extent of SU $^{13}\text{C}_6$ labeling we determined in these samples might be considered to be surprising and may point to bioregulation of endogenous serum SA.

For more than a century the focus has predominantly been on the properties of aspirin, the pro-drug of SA. It is only recently that the *in vivo* efficacy of SA as an anti-inflammatory has been adequately explained—in terms of inhibition of Cox-2 gene transcription. Given the lability of its acetyl ester (aspirin) within the narrow pH range of 2–3, other *in vitro* Cox-independent effects, such as mediation of apoptosis (25) and inhibition of angiogenesis (26), may also be attributable to SA rather than its pro-drug. Other diverse effects of SA continue to be reported, such as the surprising protective effects of lower dose SA in a mouse heart model of myocardial ischemia (27). The mechanism by which aspirin (and SA *in vitro*) has antitumoral actions is unclear, but a recent observation that cell proliferation is dependent on mitochondrial Ca^{2+} uptake and inhibited by low-level SA may be relevant (28).

SA is widely found in the animal kingdom. We have adduced evidence for its biosynthesis from benzoic acid in man. These observations are, we suggest, appropriately assessed in light of the many effects of aspirin, its pro-drug. It is, we suspect,

increasingly likely that SA is a biopharmaceutical with a central, broadly defensive, role in animals as in plants. This simple organic chemical is, we propose, likely to become increasingly recognized as an animal bioregulator, perhaps in a class of its own. Intriguingly, as a phytohormone it may have differential, concentration-dependent, effects on programmed cell death and surrounding tissue protection (29). Some of the tissue effects of SA already described (5, 6, 25–28) raise the probability of just such a hybrid function, perhaps at a critical point in apoptosis and/or inflammation, in animals as in plants.

If we are right that SA is not just an important phytochemical but also a key biopharmaceutical, its circulating level might well be subject to homeostatic control and not be solely influenced by dietary SA with or without benzoic acid intake.

LITERATURE CITED

- (1) Dangl, J. *Nature* **1998**, *394*, 525–527.
- (2) Sneader, W. *Pharm. J.* **1997**, *259*, 614–617.
- (3) Needs, C. J.; Brooks, P. M. *Clin. Pharmacokinet.* **1985**, *10*, 164–177.
- (4) Higg, G. A.; Salmon, J. A.; Henderson, B.; Vane, J. R. *Proc. Natl. Acad. Sci. U.S.A.* **1987**, *84*, 1417–1420.
- (5) Xu, X.-M.; Scansores-Garcia, L.; Chen, X.-M.; Matjevic-Aleksic, N.; Min, D.; Wu, K. K. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*, 5292–5297.
- (6) Wu, K. K. *Circulation* **2000**, *102*, 2022–2023.
- (7) Paterson, J. R.; Blacklock, C.; Campbell, G.; Wiles, D.; Lawrence, J. R. *J. Clin. Pathol.* **1998**, *51*, 502–505.
- (8) Baxter, G. J.; Lawrence, J. R.; Graham, A. B.; Wiles, D.; Paterson, J. R. *Ann. Clin. Biochem.* **2002**, *39*, 50–55.
- (9) Blacklock, C. J.; Lawrence, J. R.; Wiles, D.; Malcolm, E. A.; Gibson, I. H.; Kelly, C. J.; Paterson, J. R. *J. Clin. Pathol.* **2001**, *54*, 553–555.
- (10) Lawrence, J. R.; Peter, R.; Baxter, G. J.; Robson, J.; Graham, A. B.; Paterson, J. R. *J. Clin. Pathol.* **2003**, *56*, 651–653.
- (11) Paterson, J. R.; Srivastava, R.; Baxter, G. J.; Graham, A. B.; Lawrence, J. R. *J. Agric. Food Chem.* **2006**, *54*, 2891–2896.
- (12) Spadafranca, A.; Bertoli, S.; Fioriello, G.; Testolin, G.; Battezzati, A. *Br. J. Nutr.* **2007**, 1–5.
- (13) El-Basyouni, S.; Chen, D.; Ibrahim, R. K.; Neish, A. C.; Towers, G. H. N. *Phytochemistry* **1964**, *3*, 485–492.
- (14) Yalpini, M.; Leon, J.; Lawton, M. A.; Raskin, I. *Plant Physiol.* **1993**, *103*, 315–321.
- (15) Zuo, Y.; Wang, C.; Zhan, J. *J. Agric. Food Chem.* **2002**, *50*, 3789–3794.
- (16) Zhang, K.; Zuo, Y. *J. Agric. Food Chem.* **2004**, *52*, 222–227.
- (17) Armstrong, M. D.; Chao, F.-C.; Parker, V. J.; Wall, P. E. *Proc. Soc. Exp. Biol. Med.* **1955**, *90*, 675–679.
- (18) Young, D. S. *Clin Chem* **1970**, *16*, 681–686.
- (19) Swain, R.; Dutton, S. P.; Truswell, A. S. *J. Am. Diet. Assoc.* **1985**, *85*, 950–960.
- (20) Venema, D. P.; Hollman, P. C. H.; Janssen, P. L. T. M. K. *J. Agric. Food Chem.* **1996**, *44*, 1762–1767.
- (21) Variyar, P. S.; Bandyopadhyay, C. *J. Spices Aromatic Crops* **1995**, *4*, 129–134.
- (22) Robertson, G. I.; Kermode, W. J. *J. Sci. Food Agric.* **1981**, 833–836.
- (23) Janssen, P. L. T. M. K.; Hollman, P. C. H.; Reichman, E.; et al. *Am. J. Clin. Nutr.* **1996**, *64*, 743–747.
- (24) Bekersky, I.; Colburn, W. A.; Fishman, L.; Kaplan, S. A. *Drug Metab. Dispos.* **1980**, *8*, 319–324.
- (25) Stark, L. A.; Din, F. V. M.; Zwacke, R. M.; Dunlop, M. G. *FASEBJ* **2001**, *15*, 1273–1276.
- (26) Borthwick, G. M.; Johnson, A. S.; Partington, M.; Burn, J.; Wilson, R.; Arthur, H. M. *FASEB J.* **2006**, *20*, 2009–2016.
- (27) Farthing, D.; Gehr, L.; Karnes, H. T.; Sica, D.; Gehr, T.; Larus, T.; Farthing, C.; Xi, L. *Biomarkers* **2007**, *12* (6), 623–634.
- (28) Nunez, L.; Valero, R.; Senovilla, L.; Sanz-Blasco, S.; Garcia-Sancho, J.; Villalobos, C. *J. Physiol.* **2006**, 57–73.
- (29) Alvarez, M. E. *Plant Mol. Biol.* **2000**, *44*, 429–442.

Received for review April 25, 2008. Revised manuscript received August 7, 2008. Accepted September 9, 2008.

JF800974Z